See the DrugPatentWatch profile for tigecycline

Yes, Tigecycline can be used for Urinary Tract Infections (UTIs) caused by resistant bacteria, under certain conditions. Tigecycline is an antibiotic that is used to treat various types of bacterial infections. It is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria, including some that are resistant to other antibiotics.

According to the drug label approved by the U.S. Food and Drug Administration (FDA), Tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. However, the label also states that "the safety and effectiveness of Tigecycline in treating UTIs have not been established" [1].

Despite the lack of specific FDA approval for UTIs, Tigecycline has been used off-label for this indication. A study published in the Journal of Chemotherapy in 2013 found that Tigecycline was effective in treating UTIs caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, a type of bacteria that is often resistant to multiple antibiotics [2].

It is important to note that the use of Tigecycline for UTIs should be based on the clinical judgment of the healthcare provider, taking into account the specific circumstances of the patient and the bacteria causing the infection. The potential benefits of using Tigecycline should be weighed against the potential risks, including the risk of developing antibiotic resistance [3].

In summary, Tigecycline can be used for UTIs caused by resistant bacteria, but its use should be based on a careful evaluation of the individual patient's needs and the potential risks and benefits.

Sources:
[1] Tigecycline [Tygacil] for injection, for intravenous use. Full Prescribing Information. Pfizer Labs. December 2017. Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021867s021lbl.pdf>.
[2] Falagas ME, Karageorgopoulos DE, Rafailidis PI, Matthaiou DK. Tigecycline for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review. J Chemother. 2013 Mar;25(2):125-30. doi: 10.1179/1973987012Y.0000000012.
[3] Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Available at: <https://www.cdc.gov/drugresistance/biggest-threats.html>.
[4] DrugPatentWatch. Tigecycline. Available at: <https://www.drugpatentwatch.com/drugs/tigecycline>.